Effect of daprodustat on renal anemia in patients with chronic kidney disease
Not Applicable
- Conditions
- chronic kidney disease
- Registration Number
- JPRN-UMIN000041546
- Lead Sponsor
- Saitama Tsukinomori Clinic
- Brief Summary
The median dose of darbepoetin before switching was 40 micrograms/wk, and all subjects received daprodustat 4 mg orally once daily at the time of switching. After that, the dose of daprodustat was adjusted appropriately to achieve the guideline target Hb of 10-12g/dL. Hb was 10.9 + 0.4(SE)g/dL when switched to daprodustat. Hb levels did not change significantly until 12 months and were maintained at 10-12g/dL.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
Patients complicated with serious diseases such as malignancy, heart failure (NYHA III degrees or more), and liver cirrhosis
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Hemoglobin concentration, serum iron, transferrin saturation, serum ferritin, hepcidin
- Secondary Outcome Measures
Name Time Method